Nurix therapeutics announces clearance of investigational new drug application for nx-5948 supporting plans to expand enrollment to u.s. clinical sites

Nx-5948 is being evaluated in patients with relapsed and refractory b-cell malignancies

NRIX Ratings Summary

NRIX Quant Ranking